Publications Michael Basler

  • Mah MM, Basler M, Groettrup M. 2019. The ubiquitin-like modifier FAT10 is required for normal IFN-γ production by activated CD8+ T cells. Mol Immunol Apr;108:111-120. doi: 10.1016/j.molimm.2019.02.010. Epub 2019 Feb 25.
  • Basler M, Groettrup M. 2019. Testing the Impact of Protease Inhibitors in Antigen Presentation Assays. Methods Mol Biol 1988:59-69. doi: 10.1007/978-1-4939-9450-2_5.
  • Li J, Koerner J, Basler M, Brunner T, Kirk CJ, Groettrup M. 2019. Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors. Kidney Int Jan 22. pii: S0085-2538(18)30823-8. doi: 10.1016/j.kint.2018.10.022. [Epub ahead of print].
  • Basler M, Li J, Groettrup M. 2019. On the role of the immunoproteasome in transplant rejection. Immunogenetics Sep 15. doi: 10.1007/s00251-018-1084-0. [Epub ahead of print].
  • Schmidt C, Berger T, Groettrup M, Basler M. 2018. Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis. Front Immunol 9 (2018). - 2386. - eISSN 1664-3224.
  • Basler M, Lindstrom MM, LaStant JJ, Bradshaw JM, Owens TD, Schmidt C, Maurits E, Tsu C, Overkleeft HS, Kirk CJ, Langrish CL, Groettrup M. 2018. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity. EMBO Rep Oct 2. pii: e46512. doi: 10.15252/embr.201846512. [Epub ahead of print].
  • Treise I, Huber EM, Klein-Rodewald T, Heinemeyer W, Grassmann SA, Basler M, Adler T, Rathkolb B, Helming L, Andres C, Klaften M, Landbrecht C, Wieland T, Strom TM, McCoy KD, Macpherson AJ, Wolf E,Groettrup M, Ollert M, Neff F, Gailus-Durner V, Fuchs H, Hrabě de Angelis M, Groll M, Busch DH. 2018. Defective immuno- and thymoproteasome assembly causes severe immunodeficiency. Sci Rep Apr 13;8(1):5975. doi: 10.1038/s41598-018-24199-0.
  • Schregle R, Mah MM, Mueller S, Aichem A, Basler M, Groettrup M. 2018. The expression profile of the ubiquitin-like modifier FAT10 in immune cells suggests cell type-specific functions. Immunogenetics Mar 5. doi: 10.1007/s00251-018-1055-5. [Epub ahead of print].
  • Basler M, Maurits E, de Bruin G, Koerner J, Overkleeft HS, Groettrup M. 2018. Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome. Br J Pharmacol an;175(1):38-52. doi: 10.1111/bph.14069. Epub 2017 Nov 29.
  • Basler M, Mundt S, Groettrup M. 2018. The immunoproteasome subunit LMP7 is required in the murine thymus for filling up a hole in the T cell repertoire. Eur J Immunol 48(3):419-429.
  • Li J, Basler M, Alvarez G, Brunner T, Kirk CJ, Groettrup M. 2017. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation. Kidney Int Dec 4. pii: S0085-2538(17)30773-1. doi: 10.1016/j.kint.2017.09.023. [Epub ahead of print].
  • Mundt S, Basler M, Sawitzki B, Groettrup M. 2017. No prolongation of skin allograft survival by immunoproteasome inhibition in mice. Mol Immunol 88:32-37.
  • Bitzer A, Basler M, Krappmann D, Groettrup M. 2017. Immunoproteasome subunit deficiency has no influence on the canonical pathway of NF-κB activation. Mol Immunol. 83:147-53.
  • Mundt S, Basler M, Buerger S, Engler H, Groettrup M. 2016. Inhibiting the immunoproteasome exacerbates the pathogenesis of systemic Candida albicans infection in mice. Scientific Reports in press.
  • Bitzer A, Basler M, Groettrup M. 2016. Chaperone BAG6 is dispensable for MHC class I antigen processing and presentation. Mol Immunol Jan;69:99-105. doi: 10.1016/j.molimm.2015.11.004. Epub 2015 Nov 17.
  • Mundt S, Engelhardt B, Kirk CJ, Groettrup M, Basler M. 2016. Inhibition and deficiency of the immunoproteasome subunit LMP7 attenuates LCMV-induced meningitis. Eur J Immunol Jan;46(1):104-13. doi: 10.1002/eji.201545578. Epub 2015 Nov 2.
  • Basler M, Mundt S, Bitzer A, Schmidt C, Groettrup M. 2015. The immunoproteasome: a novel drug target for autoimmune diseases. Clin Exp Rheumatol Jul-Aug;33(4 Suppl 92):S74-9. Epub 2015 Oct 12.
  • Buerger S, Herrmann VL, Mundt S, Trautwein N, Groettrup M, Basler M. 2015. The Ubiquitin-like Modifier FAT10 Is Selectively Expressed in Medullary Thymic Epithelial Cells and Modifies T Cell Selection. J Immunol Sep 23. pii: 1500592. [Epub ahead of print].
  • Basler M, Buerger S, Groettrup M. 2015. The ubiquitin-like modifier FAT10 in antigen processing and antimicrobial defense. Mol Immunol May 13. pii: S0161-5890(15)00371-5. doi: 10.1016/j.molimm.2015.04.012. [Epub ahead of print].
  • Mundt S, Groettrup M, Basler M. 2015. Analgesia in mice with experimental meningitis reduces pain without altering immune parameters. ALTEX Mar 24. doi: http://dx.doi.org/10.14573/altex.1502021. [Epub ahead of print].
  • Spinnenhirn V, Farhan H, Basler M, Aichem A, Canaan A, Groettrup M. 2014. The ubiquitin-like modifier FAT10 decorates autophagy targeted Salmonella and contributes to resistance of mice. J Cell Sci Sep 30. pii: jcs.152371. [Epub ahead of print].
  • Basler M, Mundt S, Muchamuel T, Moll C, Jiang J, Groettrup M, Kirk CJ. 2014. Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med 6(2):226-238.
  • Nathan JA, Spinnenhirn V, Schmidtke G, Basler M, Groettrup M, Goldberg AL. 2013. Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell 152(5):1184-1194.
  • Basler M, Groettrup M. 2013. Using protease inhibitors in antigen presentation assays. Methods Mol Biol 960:31-39.
  • Basler M, Kirk CJ, Groettrup M. 2013. The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol Feb;25(1):74-80. doi: 10.1016/j.coi.2012.11.004. Epub 2012 Dec 6.
  • Kalim KW, Basler M, Kirk CJ, Groettrup M. 2012. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol 189(8):4182-4193.
  • Basler M, Lauer C, Moebius J, Weber R, Przybylski M, Kisselev AF, Tsu C, Groettrup M. 2012. Why the structure but not the activity of the immunoproteasome subunit low molecular mass polypeptide 2 rescues antigen presentation. J Immunol 189(4):1868-1877.
  • Basler M, Groettrup M. 2012. Immunoproteasome-specific inhibitors and their application. Methods Mol Biol 832:391-401.
  • Huber EM*, Basler M*, Schwab R*, Kirk CJ, Heinemeyer W, Groettrup M, Groll M. 2012. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 148(4):727-738. * shared first authorship
  • Basler M, Beck U, Kirk CC, Groettrup M. 2011. The antiviral immune response in mice devoid of immunoproteasome activity. J Immunol 187(11):5548-5557.
  • Sommershof A, Basler M, Riether C, Engler H, Groettrup M. 2010. Attenuation of the cytotoxic T lymphocyte response to lymphocytic choriomeningitis virus in mice subjected to chronic social stress. Brain Behav Immun 5(2):340-348.
  • Moebius J, Van den Broek M, Groettrup M, Basler M. 2010. Immunoproteasomes are essential for survival and expansion of T cells in virus infected mice. Eur J Immunol 40(12):3439-49.
  • Kremer M, Henn A, Kolb C, Basler M, Moebius J, Guillaume B, Leist M, Van Den Eynde BJ, Groettrup M. 2010. Reduced immunoproteasome formation and accumulation of immunoproteasomal percursors in the brain of LCMV-infected mice. J Immunol 185(9):5549-60.
  • Basler M, Dajee M, Moll C, Groettrup M, Kirk CJ. 2010. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome1.J Immunol 185(1):634-641.
  • Groettrup M, Kirk CJ, Basler M. 2010. Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol 10(1):73-78.
  • Basler M, Lauer C, Beck U, Groettrup M. 2009. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 183(10):6145-6150.
  • Muchamuel T*, Basler M*, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ , Groettrup M. 2009. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15(7):781-787. * shared first authorship
  • Basler M, Groettrup M. 2007. No essential role for tripeptidyl peptidase II for the processing of LCMV-derived T cell epitopes. Eur J Immunol 37(4):896-904.
  • Basler M, Groettrup M. 2007. Advances in prostate cancer immunotherapies. Drugs Aging 24(3):197-221.
  • Basler M, Moebius J, Elenich L, Groettrup M, Monaco JJ. 2006. An altered T cell repertoire in MECL-1-deficient mice. J Immunol 176(11):6665-6672.
  • Basta S, Stoessel R, Basler M, van den Broek M, Groettrup M. 2005. Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J Immunol 175(2):796-805.
  • Basler M, Youhnovski N, van den Broek M, Przybylski M, Groettrup M. 2004. Immunoproteasomes downregulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J Immunol 173(6):3925-34.
  • Khan S, Zimmermann A, Basler M, Groettrup M, Hengel H. 2004. A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction. J Virol 78(4):1831-42.
  • Probst HC, Tschannen K, Gallimore A, Martinic M, Basler M, Dumrese T, Jones E, van den Broek MF. 2003. Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J Immunol 171(10):5412-22.
  • Froeschke M, Basler M, Groettrup M, Dobberstein B. 2003. Long-lived signal peptide of lymphocytic choriomeningitis virus glycoprotein pGP-C. J Biol Chem 278(43):41914-20.